Popular Weight Loss Drugs Linked to Rare Risk of Sudden Vision Loss

Scientists have found that some popular medicines used to treat diabetes and obesity may be linked to a small rise in the risk of a rare eye problem. The drugs — including Ozempic, Wegovy, Mounjaro, and Zepbound — belong to a group called GLP-1 medications. A new study says people taking these drugs were slightly more likely to develop a condition that can cause sudden vision loss. Researchers shared their findings in a medical journal called the Annals of Internal Medicine.

The eye condition is called ischemic optic neuropathy, or ION. It happens when not enough blood reaches the optic nerve, which is the nerve that carries picture information from your eye to your brain. When this nerve is damaged, a person can lose part of their vision suddenly and without any pain. In some cases, the damage can be permanent and never fully heal.

Doctors want to be clear that the risk is very small. Fewer than one extra person out of every 2,000 people taking these drugs got the eye condition compared to those on other diabetes medicines. Dr. Chintan Dave, a researcher at Rutgers University, told Newsweek that patients should not stop taking their medicine just because of this finding. He said the drugs still have very strong benefits for treating diabetes, obesity, and heart and kidney health.

Researchers at Rutgers University studied health insurance records from adults between the ages of 18 and 65 who had type 2 diabetes. They looked at data collected between 2017 and 2022. The team compared people who took GLP-1 drugs with people who took two other types of diabetes medicine. This helped them see if the eye condition showed up more often in people taking GLP-1 drugs.

The numbers showed a real but small difference. Among GLP-1 users, about 8.5 out of every 10,000 people developed the eye problem over 18 months. Among people taking one of the comparison drugs, only about 5.5 out of every 10,000 people developed it. That works out to roughly three or four extra cases per 10,000 patients. The researchers were careful to say this does not prove the drugs cause the problem — it only shows a connection.

More than three out of four cases of ION are a type called NAION, which usually affects just one eye. It can cause blurry vision, dimming, or a missing piece of what a person can see. Total blindness from this condition is rare, but the vision problems that do occur are often long-lasting. This makes early attention very important.

An eye doctor named Mr. Mfazo Hove explained what symptoms people should watch for. These include a sudden loss of vision or blurring in one eye, vision that looks dim, changes in how colors appear, or blank spots in what you can see. He said that even though these symptoms are not always caused by ION, they should never be ignored. He urged anyone who notices these changes to get medical help right away.

Experts agree that the benefits of GLP-1 drugs are still very strong for most patients. These medicines help lower blood sugar, cause significant weight loss, and reduce the risk of heart disease. Doctors say the right response is to stay alert and watch for eye changes — not to panic or stop the medicine. Mr. Hove said it best: 'The right response to this research is vigilance and monitoring, not alarm.'

This study is part of a growing effort to fully understand the safety of GLP-1 drugs, which have become very popular in recent years. Earlier studies gave mixed results — some found a small increase in eye risk, while others found no added risk at all. Scientists will keep studying this topic to learn more. For now, anyone taking a GLP-1 drug who notices a sudden change in their vision should see a doctor immediately.